SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom
Background: Mandatory Day 2 and Day 8 PCR testing and variant sequencing of international arrivals has been recently introduced by the UK Government to mitigate against cross-border transmission of high-risk SARS-CoV-2 variants. Methods: SARS-CoV-2 testing and sequencing combines TaqPath CE-IVD COVI...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-08-01
|
| Series: | EClinicalMedicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589537021003011 |
| _version_ | 1818353875189497856 |
|---|---|
| author | Gareth H Williams Alexander Llewelyn Ruben Brandao Kaiya Chowdhary Keeda-Marie Hardisty Marco Loddo |
| author_facet | Gareth H Williams Alexander Llewelyn Ruben Brandao Kaiya Chowdhary Keeda-Marie Hardisty Marco Loddo |
| author_sort | Gareth H Williams |
| collection | DOAJ |
| description | Background: Mandatory Day 2 and Day 8 PCR testing and variant sequencing of international arrivals has been recently introduced by the UK Government to mitigate against cross-border transmission of high-risk SARS-CoV-2 variants. Methods: SARS-CoV-2 testing and sequencing combines TaqPath CE-IVD COVID-19 RT-PCR with Ion AmpliSeq SARS-CoV-2 Next Generation Sequencing Assay. Retrospective analysis of test trending data was performed from initiation of testing on the 11th March through to the 14th April 2021. Findings: During this time interval, 203,065 SARS-CoV-2 PCR tests were performed, with 3,855 samples testing positive, giving a prevalence of 1.9%. In total 1,913 SARS-CoV-2 genomes were sequenced from positive cases with Ct values < 30 and 1,635 (85.5%) sequences passed quality metrics for lineage analysis. A high diversity of 49 different SARS-CoV-2 variants were identified, including the VOCs B.1.1.7 (Kent; 80.6%), B.1.351 (South Africa; 4.2%), B.1.617.2 (India; 1.7%), P.1 (Brazil; 0.4%) and B.1.1.7 with E484K (Bristol; 0.2%). Vaccine effectiveness was age-related and dose-dependent, ranging from 5% in > 60 with a single dose to 83% in <60 with both doses of a vaccine. Viral load was variant dependent with the B.1.617.2 showing a 21 fold increase in viral copy number compared to the other variants. Interpretation: The unexpectedly high prevalence of COVID-19 infection in UK arrivals is associated with a rich diversity of SARS-CoV-2 high risk variants entering the UK including the VOC B.1.617.2. Vaccination does not preclude infection and its effectiveness is significantly age-dependent and impacted by variant type. The rapid high-throughput test and sequence workflow we have adopted is particularly suited to the monitoring of cross border transmission and enables immediate public health interventions. Funding: Data analysis conducted in this study was limited to secondary use of information previously collected in the course of normal care. |
| first_indexed | 2024-12-13T19:16:28Z |
| format | Article |
| id | doaj.art-62e8497b84ce4af49676fafdb5b49b98 |
| institution | Directory Open Access Journal |
| issn | 2589-5370 |
| language | English |
| last_indexed | 2024-12-13T19:16:28Z |
| publishDate | 2021-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | EClinicalMedicine |
| spelling | doaj.art-62e8497b84ce4af49676fafdb5b49b982022-12-21T23:34:16ZengElsevierEClinicalMedicine2589-53702021-08-0138101021SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United KingdomGareth H Williams0Alexander Llewelyn1Ruben Brandao2Kaiya Chowdhary3Keeda-Marie Hardisty4Marco Loddo5Oncologica UK Ltd. Suite 2, The Newnham Building, Chesterford Research Park, Cambridge CB10 1XL, United KingdomOncologica UK Ltd. Suite 2, The Newnham Building, Chesterford Research Park, Cambridge CB10 1XL, United KingdomOncologica UK Ltd. Suite 2, The Newnham Building, Chesterford Research Park, Cambridge CB10 1XL, United KingdomOncologica UK Ltd. Suite 2, The Newnham Building, Chesterford Research Park, Cambridge CB10 1XL, United KingdomOncologica UK Ltd. Suite 2, The Newnham Building, Chesterford Research Park, Cambridge CB10 1XL, United Kingdom; Corresponding author.Oncologica UK Ltd. Suite 2, The Newnham Building, Chesterford Research Park, Cambridge CB10 1XL, United KingdomBackground: Mandatory Day 2 and Day 8 PCR testing and variant sequencing of international arrivals has been recently introduced by the UK Government to mitigate against cross-border transmission of high-risk SARS-CoV-2 variants. Methods: SARS-CoV-2 testing and sequencing combines TaqPath CE-IVD COVID-19 RT-PCR with Ion AmpliSeq SARS-CoV-2 Next Generation Sequencing Assay. Retrospective analysis of test trending data was performed from initiation of testing on the 11th March through to the 14th April 2021. Findings: During this time interval, 203,065 SARS-CoV-2 PCR tests were performed, with 3,855 samples testing positive, giving a prevalence of 1.9%. In total 1,913 SARS-CoV-2 genomes were sequenced from positive cases with Ct values < 30 and 1,635 (85.5%) sequences passed quality metrics for lineage analysis. A high diversity of 49 different SARS-CoV-2 variants were identified, including the VOCs B.1.1.7 (Kent; 80.6%), B.1.351 (South Africa; 4.2%), B.1.617.2 (India; 1.7%), P.1 (Brazil; 0.4%) and B.1.1.7 with E484K (Bristol; 0.2%). Vaccine effectiveness was age-related and dose-dependent, ranging from 5% in > 60 with a single dose to 83% in <60 with both doses of a vaccine. Viral load was variant dependent with the B.1.617.2 showing a 21 fold increase in viral copy number compared to the other variants. Interpretation: The unexpectedly high prevalence of COVID-19 infection in UK arrivals is associated with a rich diversity of SARS-CoV-2 high risk variants entering the UK including the VOC B.1.617.2. Vaccination does not preclude infection and its effectiveness is significantly age-dependent and impacted by variant type. The rapid high-throughput test and sequence workflow we have adopted is particularly suited to the monitoring of cross border transmission and enables immediate public health interventions. Funding: Data analysis conducted in this study was limited to secondary use of information previously collected in the course of normal care.http://www.sciencedirect.com/science/article/pii/S2589537021003011 |
| spellingShingle | Gareth H Williams Alexander Llewelyn Ruben Brandao Kaiya Chowdhary Keeda-Marie Hardisty Marco Loddo SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom EClinicalMedicine |
| title | SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom |
| title_full | SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom |
| title_fullStr | SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom |
| title_full_unstemmed | SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom |
| title_short | SARS-CoV-2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the United Kingdom |
| title_sort | sars cov 2 testing and sequencing for international arrivals reveals significant cross border transmission of high risk variants into the united kingdom |
| url | http://www.sciencedirect.com/science/article/pii/S2589537021003011 |
| work_keys_str_mv | AT garethhwilliams sarscov2testingandsequencingforinternationalarrivalsrevealssignificantcrossbordertransmissionofhighriskvariantsintotheunitedkingdom AT alexanderllewelyn sarscov2testingandsequencingforinternationalarrivalsrevealssignificantcrossbordertransmissionofhighriskvariantsintotheunitedkingdom AT rubenbrandao sarscov2testingandsequencingforinternationalarrivalsrevealssignificantcrossbordertransmissionofhighriskvariantsintotheunitedkingdom AT kaiyachowdhary sarscov2testingandsequencingforinternationalarrivalsrevealssignificantcrossbordertransmissionofhighriskvariantsintotheunitedkingdom AT keedamariehardisty sarscov2testingandsequencingforinternationalarrivalsrevealssignificantcrossbordertransmissionofhighriskvariantsintotheunitedkingdom AT marcoloddo sarscov2testingandsequencingforinternationalarrivalsrevealssignificantcrossbordertransmissionofhighriskvariantsintotheunitedkingdom |